Cargando…
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
A major impediment to successful use of therapeutic protein drugs is their ability to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number of patients. To this aim, in silico, in vitro, and in vivo tools have been developed to assess sequence and oth...
Autores principales: | Ducret, Axel, Ackaert, Chloé, Bessa, Juliana, Bunce, Campbell, Hickling, Timothy, Jawa, Vibha, Kroenke, Mark A., Lamberth, Kasper, Manin, Anaïs, Penny, Hweixian L., Smith, Noel, Terszowski, Grzegorz, Tourdot, Sophie, Spindeldreher, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726688/ https://www.ncbi.nlm.nih.gov/pubmed/34923896 http://dx.doi.org/10.1080/19420862.2021.1993522 |
Ejemplares similares
-
10(th) European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
por: Tourdot, S., et al.
Publicado: (2020) -
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022) -
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016) -
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
por: Joubert, Marisa K., et al.
Publicado: (2016) -
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
por: Jawa, Vibha, et al.
Publicado: (2020)